Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

Nan Geng,Lina Ma,Yi Jin,Junfeng Lu,Yanhong Zheng,Junli Wang,Xiaoxiao Wang,Xinyue Chen

DOI: https://doi.org/10.3390/diagnostics14010118

IF: 3.6

2024-01-04

Diagnostics

Abstract:To evaluate the prediction model comprised of patients' laboratory results and single-nucleotide polymorphism (SNP) markers of host gene for the clearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) who underwent interferon (IFN)-α therapy, this prospective case–control study enrolled 131 patients with CHB who underwent IFN-α-based regimens in our hospital between January 2015 and September 2019. Among them, 56 cases were without HBsAg clearance, while the other 75 cases had HBsAg clearance. Multivariable logistic regression analysis showed that CYP27B1 rs4646536 (odd ratio [OR] = 0.155, 95% CI: 0.030–0.807, p = 0.027), PAK4 rs9676717 (OR = 11.237, 95% CI: 1.768–71.409, p = 0.010), IL28B rs12979860 (OR = 0.059, 95% CI: 0.006–0.604, p = 0.017), baseline HBsAg (OR = 0.170, 95% CI: 0.040–0.716, p = 0.016), and HBeAg status (OR = 3.971, 95% CI: 1.138–13.859, p = 0.031) were independently associated with HBsAg clearance. The model that included rs3077, rs4646536, rs9676717, rs2850015, rs12979860, baseline HBsAg, HBeAg status, and HBV DNA had the best prediction performance for HBsAg clearance prediction, with AUC = 0.877, 80% sensitivity, and 81% specificity. In conclusion, laboratory results and gene polymorphisms before treatment might have a good predictive value for HbsAg clearance after IFN-α treatment in CHB.

medicine, general & internal

What problem does this paper attempt to address?

The paper attempts to address the issue of predicting the likelihood of hepatitis B surface antigen (HBsAg) clearance after interferon (IFN-α) treatment in patients with chronic hepatitis B (CHB). The study employs a prospective case-control design, combining patients' laboratory test results and host gene single nucleotide polymorphism (SNP) markers to establish a predictive model to assess the impact of these factors on HBsAg clearance rates.

Specifically, the study identifies the following factors as independently associated with IFN-α-induced HBsAg clearance:
- CYP27B1 rs4646536
- PAK4 rs9676717
- IL28B rs12979860
- Baseline HBsAg levels
- HBeAg status

The predictive model that integrates these factors demonstrates good predictive performance (AUC = 0.877), with high sensitivity and specificity. This suggests that laboratory results and genetic polymorphisms may have good predictive value before treatment, helping to identify which patients are likely to benefit from IFN-α therapy.